Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 5/20 | 0.68 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.68 |
| ▸ | MAPT | P10636 | 9/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.64 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.64 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.64 |
| ▸ | HPGD | P15428 | 4/20 | 0.64 |
| ▸ | ALOX15 | P16050 | 3/20 | 0.64 |
| ▸ | RAB9A | P51151 | 3/20 | 0.64 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.55 |
| ▸ | MEN1 | O00255 | 4/20 | 0.53 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.53 |
| ▸ | LMNA | P02545 | 3/20 | 0.53 |
| ▸ | NPC1 | O15118 | 2/20 | 0.53 |
| ▸ | TSHR | P16473 | 2/20 | 0.49 |
| ▸ | PDE3B | Q13370 | 1/20 | 0.47 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.47 |
| ▸ | GRM6 | O15303 | 2/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8143273 | 0.94 | GAA (0.60) | GAAMAPK1MAPTALDH1A1HSD17B10 | |
| SCHEMBL3113232 | 0.88 | GAA (0.66) | GAAMAPK1MAPTALDH1A1HSD17B10 | |
| SCHEMBL1564819 | 0.86 | MAPT (0.59) | GAAMAPK1MAPTALDH1A1HSD17B10 | |
| SCHEMBL5864713 | 0.86 | GAA (0.63) | GAAMAPK1MAPTALDH1A1HSD17B10 | |
| SCHEMBL5422196 | 0.83 | ALOX15 (0.51) | GAAMAPK1MAPTALDH1A1HSD17B10 | |
| SCHEMBL5865211 | 0.81 | ALOX15 (0.56) | GAAMAPTALDH1A1HSD17B10SMN1; SMN2 | |
| SCHEMBL1973680 | 0.81 | GAA (1.00) | GAAMAPK1MAPTALDH1A1HSD17B10 | |
| SCHEMBL23827481 | 0.81 | GAA (0.56) | GAAMAPK1MAPTALDH1A1HSD17B10 | |
| SCHEMBL1973534 | 0.81 | GAA (0.56) | GAAMAPK1MAPTALDH1A1HSD17B10 | |
| SCHEMBL5864678 | 0.80 | GAA (0.59) | GAAMAPK1MAPTALDH1A1HSD17B10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160376286-A1 | Pyrimidin-4-one derivatives and their use in the tratement, amelioration or prevention of a viral disease | F. HOFFMAN-LA ROCHE LTD | 2016-12-29 | — | — | US | disclosed |
| US-20160297763-A1 | Heteroaryl hydroxamic acid derivatives and their use in the treatment, amelioration or prevention of a viral disease | F. HOFFMANN-LA ROCHE LTD (CH) | 2016-10-13 | — | — | US | disclosed |
| EP-2794616-B1 | PYRIMIDIN-4-ONE DERIVATIVES AND THEIR USE IN THE TREATMENT, AMELIORATION OR PREVENTION OF A VIRAL DISEASE | HOFFMANN LA ROCHE (CH) | 2016-06-29 | — | — | EP | disclosed |
| EP-2794616-A1 | PYRIMIDIN-4-ONE DERIVATIVES AND THEIR USE IN THE TREATMENT, AMELIORATION OR PREVENTION OF A VIRAL DISEASE | F.HOFFMANN-LA ROCHE AG (CH) | 2014-10-29 | — | — | EP | disclosed |
| EP-2776396-A2 | HETEROARYL HYDROXAMIC ACID DERIVATIVES AND THEIR USE IN THE TREATMENT, AMELIORATION OR PREVENTION OF A VIRAL DISEASE | F.HOFFMANN-LA ROCHE AG (CH) | 2014-09-17 | — | — | EP | disclosed |
| US-20130102601-A1 | Pyrimidin-4-one derivatives and their use in the treatment, amelioration or prevention of a viral disease | F. HOFFMANN-LA ROCHE LTD (CH) | 2013-04-25 | — | — | US | disclosed |
| WO-2013057251-A2 | HETEROARYL HYDROXAMIC ACID DERIVATIVES AND THEIR USE IN THE TREATMENT, AMELIORATION OR PREVENTION OF A VIRAL DISEASE | F. HOFFMANN-LA ROCHE AG (CH) | 2013-04-25 | — | — | WO | disclosed |
| US-20130102600-A1 | Heteroaryl hydroxamic acid derivatives and their use in the treatment, amelioration or prevention of a viral disease | F. HOFFMANN-LA ROCHE LTD (CH) | 2013-04-25 | — | — | US | disclosed |
| WO-2013057253-A1 | PYRIMIDIN-4-ONE DERIVATIVES AND THEIR USE IN THE TREATMENT, AMELIORATION OR PREVENTION OF A VIRAL DISEASE | F. HOFFMANN-LA ROCHE AG (CH) | 2013-04-25 | — | — | WO | disclosed |
| US-6984644-B2 | Treatment of skin disorders using thieno[2,3-D]pyrimidinediones | ASTRAZENECA AB (SE) | 2006-01-10 | — | — | US | disclosed |
| US-20030191142-A1 | Thieno[2,3-d]pyrimidinediones, their preparation and use in therapy | ASTRAZENECA AB | 2003-10-09 | — | — | US | disclosed |
| US-20020183337-A1 | For use in immunosuppression; for reducing the risk of, a reversible obstructive airways disease | ASTRAZENECA AB. | 2002-12-05 | — | — | US | disclosed |
| US-6469014-B1 | IMMUNOSUPPRESSIVE ACTIVITY | ASTRAZENECA AB (SE) | 2002-10-22 | — | — | US | disclosed |
| EP-0991653-B1 | NOVEL COMPOUNDS | ASTRAZENECA AB (SE) | 2002-10-16 | — | — | EP | disclosed |
| US-6342502-B1 | ANTIASTHMATICS | ASTRAZENECA AB (GB) | 2002-01-29 | — | — | US | disclosed |
| US-6180635-B1 | NOVEL THIENO(2,3-D)PYRIMIDINEDIONES WHICH EXHIBIT PHARMACOLOGICAL ACTIVITY, IN PARTICULAR IMMUNOSUPPRESSIVE ACTIVITY; TREATING ALLOGRAFT REJECTION | ASTRAZENECA UK LIMITED (GB) | 2001-01-30 | — | — | US | disclosed |
| EP-0991653-A1 | NOVEL COMPOUNDS | Astra Pharmaceuticals Limited (GB) | 2000-04-12 | — | — | EP | disclosed |
| WO-1998054190-A1 | NOVEL COMPOUNDS | ASTRA PHARMACEUTICALS LTD. (GB) | 1998-12-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130102601-A1 | Pyrimidin-4-one derivatives and their use in the treatment, amelioration or prevention of a viral disease | TPMT, TYMP, HPRT1 | GAA 310/4885MAPK1 1721/4885MAPT 14/4885 |
| US-20160376286-A1 | Pyrimidin-4-one derivatives and their use in the tratement, amelioration or prevention of a viral disease | TTR, TYMP, TPMT | GAA 188/4885MAPK1 2142/4885MAPT 28/4885 |
| US-20020183337-A1 | For use in immunosuppression; for reducing the risk of, a reversible obstructive airways disease | TPMT, TSLP, TYMP | GAA 2829/4885MAPK1 4538/4885MAPT 3176/4885 |
| US-20160297763-A1 | Heteroaryl hydroxamic acid derivatives and their use in the treatment, amelioration or prevention of a viral disease | ALAD, CYP27A1, FAH | GAA 42/4885MAPK1 2916/4885MAPT 79/4885 |
| US-20030191142-A1 | Thieno[2,3-d]pyrimidinediones, their preparation and use in therapy | TYMP, DPYD, TYMS | GAA 2121/4885MAPK1 4119/4885MAPT 2731/4885 |
| US-20130102600-A1 | Heteroaryl hydroxamic acid derivatives and their use in the treatment, amelioration or prevention of a viral disease | FAH, SLC10A1, OAT | GAA 34/4885MAPK1 3498/4885MAPT 54/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.